BioAgeTM
Biological Age
BioAge determines a person’s biological age, which can indicate their overall health, via vascular and metabolic indicators present in the retinal image.
Expand BioAge Regulatory information
BioAge has varying regulatory statuses depending on the region and is not yet cleared for sale in all markets. Please refer to the BioAge page or contact our support for more information and availability in your market.
CLAiRTM
Cardiovascular Risk
CLAiR unlocks the power of retinal cameras to enable them to deliver real-time, lower cost, non-invasive cardiovascular risk assessments.
Expand CLAiR Regulatory information
CLAiR has CE and UKCA marks and is cleared for sale in some regions. Please contact us to find out if CLAiR is available in your region. CLAiR is not available in the United States.
MyKidneyAITM
Chronic Kidney Disease
MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease in people with diabetes.
Expand MyKidneyAI Regulatory information
MyKidneyAI has varying regulatory statuses depending on the region and is not yet cleared for sale in all markets. Please contact our support for more information and availability in your market.
Products developed by Toku
BioAgeTM
Biological Age
BioAge determines a person’s biological age, which can indicate their overall health, via vascular and metabolic indicators present in the retinal image.
Expand BioAge Regulatory information
BioAge has varying regulatory statuses depending on the region and is not yet cleared for sale in all markets. Please refer to the BioAge page or contact our support for more information and availability in your market.
CLAiRTM
Cardiovascular Risk
CLAiR unlocks the power of retinal cameras to enable them to deliver real-time, lower cost, non-invasive cardiovascular risk assessments.
Expand CLAiR Regulatory information
CLAiR has CE and UKCA marks and is cleared for sale in some regions. Please contact us to find out if CLAiR is available in your region. CLAiR is not available in the United States.
MyKidneyAITM
Chronic Kidney Disease
MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease in people with diabetes.
Expand MyKidneyAI Regulatory information
MyKidneyAI has varying regulatory statuses depending on the region and is not yet cleared for sale in all markets. Please contact our support for more information and availability in your market.
Our AI models
Securely built on the largest, fastest growing dataset of retinal images linked to medical records.
4,300,080
Retinal images in our dataset and still counting!
Our commitment to quality
As an ISO 13485 certified company, you can trust that our products are manufactured with the highest standards of quality and safety in mind.
Our worldwide partners & investors
As seen in
If you can see the future, you can change it.
We believe every person in the world should have access to early diagnosis of health conditions before it’s too late. Toku’s CEO Ehsan Vaghefi’s father’s experience with preventable blindness inspired a lifelong commitment to fighting preventable diseases.
Click play to see how we’re helping transform healthcare.
If you can see the future, you can change it.
We believe every person in the world should have access to early diagnosis of health conditions before it’s too late. Toku’s CEO Ehsan Vaghefi’s father’s experience with preventable blindness inspired a lifelong commitment to fighting preventable diseases.
Click play to see how we’re helping transform healthcare.
